ITGAV and metabolic dysfunction-associated steatohepatitis: Recent studies have shown that RUNX2 can activate the TGF-β signaling pathway by upregulating Itgav expression in CCl4 and non-alcoholic steatohepatitis (NASH) mouse models [14].